Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
that surrounds both can negatively impact patients and their treatment. Now lessons learned from the HIV epidemic are helping people living with lung cancer and their loved ones. During the first years of the HIV epidemic, some of the initial stigmatizing beliefs were that the virus only impacted men who have sex with men and that it was possible to contract it by sharing utensils or being in close confines with a person living with HIV. This helped contribute to acts of discrimination and an atmosphere of blame, and in some cases prevented people from getting diagnosed or seeking care. People diagnosed with lung cancer face similar stigma challenges because of the known link to tobacco use - despite the National Cancer Institute's estimate that 10-
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $120.00 to $130.00. They now have an "overweight" rating on the stock.MarketBeat
- Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Health Care Roundup: Market Talk [Yahoo! Finance]Yahoo! Finance
- ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/11/25 - Beat
GILD
Sec Filings
- 3/27/25 - Form ARS
- 3/27/25 - Form DEF
- 3/27/25 - Form DEFA14A
- GILD's page on the SEC website